The US Food and Drug Administration (FDA) has expanded approval of lumateperone (Caplyta) to include treatment of adults with depressive episodes associated with bipolar I and II disorder, as ...

Please provide your email address to receive an email when new articles are posted on . Researchers have uncovered important factors associated with the switch from mania to depression among ...

The approval was supported by data from two phase 3 studies that evaluated Caplyta as monotherapy and adjunctive therapy with lithium or valproate in adults with bipolar depression. The Food and Drug ...

The bipolar disorder market across the USA, Europe, and Japan is forecast to rise from $5.6 billion in 2024 to $9.4 billion ...

Dr. Harold Koenig answers the question: 'What Is Depression?' — -- Question: What is the difference between depression and manic depression (bipolar disorder)? Answer: Depression and manic ...

A presentation at the 2022 Neuroscience Education Institute (NEI) Congress focused on bipolar depression across the lifespan of the patient, the impact of an early and correct diagnosis on treatment, ...

Bipolar disorder causes extreme mood swings that range from manic highs to depressive lows, disrupting every aspect of life. Unlike ordinary mood changes everyone experiences, bipolar episodes are ...

If you have bipolar I, you likely know how exhausting its highs and lows can be. In a depressive period, you might feel so down that you don’t want to do things you normally enjoy, or even leave your ...